Cite
HARVARD Citation
Long, G. et al. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet oncology. 20 (8), pp. 1083-1097. [Online].